The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

Stock Information for Compass Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compass Therapeutics Inc.

Compass Therapeutics Provides Corporate Update
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
Compass Therapeutics to Participate in Upcoming December Investor Events
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics to Participate in Upcoming November Investor Events

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.